MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce the appointment of Sylvain Desjeans as Chief Revenue Officer. With more than 30 years of health-care industry experience, Mr. Desjeans is a seasoned leader who has successfully implemented and led large-scale strategic growth plans and global product licensing initiatives for international pharmaceutical and medical companies. He comes to MedX from tenures as Country Manager (Canada) for Aspen Pharmacare and senior leadership positions at Accucaps Industries Limited and Biovail Pharmaceuticals.
Mr. Desjeans will lead market access, customer acquisition, engagement and marketing for MedX’s teledermatology offering as the Company accelerates its international expansion efforts and continues the growth of its network of approved clinical partners across Canada, including Empower Clinics. Mr. Desjeans will also work closely with the chair of MedX’s Medical Advisory Board, Dr. Trevor Champagne, on the Company’s artificial intelligence technology, driving ongoing innovation and patient-driven product development.
"Sylvain brings a wealth of experience to our growing team as we continue to scale our operations to meet international demand and increasing uptake within the North American market,” said Robert von der Porten, Acting CEO and Chairman. "His experience, leadership and relationships will secure further market access as we set our sights on new opportunities given the growing need for teledermatology to support health-care systems, globally. His background in dermatology – and specifically working with dermatologists – will bring value to our partner clinicians and customers.”
Mr. Desjeans stated, "MedX is poised for significant international market expansion with its best-in-class SIAscopy® skin-scanning device and DermSecure® platform. This technology reduces the strain on health-care systems by offering a truly patient-centric experience, which ultimately improves patient outcomes.”
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
Teledermatology, a subspecialty of dermatology that offers safe and effective virtual care —patient assessment and diagnosis— at a distance, eliminates the need for in-person appointments. With the world navigating through ongoing COVID-19 recovery measures, teledermatology's advancement has never been more critical to patient care and outcomes.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in SIAMETRICS®, a well-regarded research system used to assess treatment effectiveness of a variety of skin conditions, including burns. The Company’s SIAscope® and other devices are manufactured in its ISO 13485 certified facility. The SIAscope® is a hand-held device that uses patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with the Company’s software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. DermSecure® meets all privacy, security and relevant regulatory requirements in Canada, the US, Brazil, and the EU. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.